Denali Therapeutics Inc (OQ:DNLI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 161 Oyster Point Blvd
Tel: N/A
IR: See website
Key People
Vicki L. Sato
Independent Chairman of the Board
Ryan J. Watts
President, Chief Executive Officer, Co-Founder, Director
Alexander O. Schuth
Co-Founder, Chief Operating Officer, Secretary
Steve Krognes
Chief Financial Officer, Treasurer
Carole Ho
Chief Medical Officer and Head of Development
Business Overview
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company's development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
Financial Overview
For the nine months ended 30 September 2019, Denali Therapeutics Inc revenues increased from $3.5M to $22M. Net loss increased 26% to $143.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research & Development Expense - Balanci increase of 33% to $127.6M (expense), Stock-based Compensation in SGA increase from $6M to $15.3M (expense).
Employees: 230 as of Jun 30, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $963.00M as of Sep 30, 2019
Annual revenue (TTM): $147.68M as of Sep 30, 2019
EBITDA (TTM): -$72.39M as of Sep 30, 2019
Net annual income (TTM): -$66.06M as of Sep 30, 2019
Free cash flow (TTM): -$27.33M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 96,031,223 as of Oct 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization